[go: up one dir, main page]

AU2001259817A1 - Methods of and compounds for inhibiting calpains - Google Patents

Methods of and compounds for inhibiting calpains

Info

Publication number
AU2001259817A1
AU2001259817A1 AU2001259817A AU5981701A AU2001259817A1 AU 2001259817 A1 AU2001259817 A1 AU 2001259817A1 AU 2001259817 A AU2001259817 A AU 2001259817A AU 5981701 A AU5981701 A AU 5981701A AU 2001259817 A1 AU2001259817 A1 AU 2001259817A1
Authority
AU
Australia
Prior art keywords
compounds
methods
calpains
inhibiting
inhibiting calpains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259817A
Inventor
Paolo B. De Petrillo
Wenshuai Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2001259817A1 publication Critical patent/AU2001259817A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001259817A 2000-05-04 2001-05-02 Methods of and compounds for inhibiting calpains Abandoned AU2001259817A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20237800P 2000-05-04 2000-05-04
US60/202,378 2000-05-04
PCT/US2001/040652 WO2001082919A2 (en) 2000-05-04 2001-05-02 Methods of and compounds for inhibiting calpains

Publications (1)

Publication Number Publication Date
AU2001259817A1 true AU2001259817A1 (en) 2001-11-12

Family

ID=22749625

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259817A Abandoned AU2001259817A1 (en) 2000-05-04 2001-05-02 Methods of and compounds for inhibiting calpains

Country Status (3)

Country Link
US (1) US6448245B1 (en)
AU (1) AU2001259817A1 (en)
WO (1) WO2001082919A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030886A2 (en) * 2001-10-05 2003-04-17 Elan Pharmaceuticals, Inc Allylamides useful in the treatment of alzheimer's disease
CA2465316A1 (en) * 2001-10-29 2003-05-08 James P. Beck Hydroxy substituted amides for the treatment of alzheimer's disease
US20030138423A1 (en) * 2001-12-14 2003-07-24 Cedars-Sinai Medical Center Method of treating inflammation with HIV-1 protease inhibitors and their derivatives
WO2004052364A1 (en) * 2002-12-06 2004-06-24 The Trustees Of Boston University METHODS FOR SUSTAINING eNOS ACTIVITY
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2602784T3 (en) * 2007-02-23 2017-02-22 Gilead Sciences, Inc. Modulators of the pharmacokinetic properties of therapeutic agents
CN101796040A (en) * 2007-07-06 2010-08-04 吉里德科学公司 Modulators of the Pharmacokinetic Properties of Therapeutic Agents
JP5629585B2 (en) * 2008-01-04 2014-11-19 ギリアード サイエンシーズ, インコーポレイテッド Inhibitor of cytochrome P450
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
EP3007556B1 (en) 2013-06-13 2020-05-20 Biomatrica, INC. Cell stabilization
EP3942931A1 (en) 2014-06-10 2022-01-26 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
CN104069117A (en) * 2014-07-03 2014-10-01 滨州医学院 Application of amprenavir in preparation of medicine for preventing or treating ischemic cardiovascular and cerebrovascular diseases
KR20250047404A (en) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 Reduction of erythrocyte sedimentation rate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DE4215874A1 (en) 1992-05-14 1993-11-18 Bayer Ag Dithiolanylglycine-containing HIV protease inhibitors of the hydroxyethylene isostear type
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE19500120A1 (en) 1995-01-04 1996-07-11 Bayer Ag New acylated pseudopeptides with trifluoromethyl-substituted 2-azabicyclooctane
WO1998020888A1 (en) 1996-11-08 1998-05-22 Japan Energy Corporation Aids remedy
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
GB9712253D0 (en) 1997-06-13 1997-08-13 Glaxo Group Ltd Antiviral compound

Also Published As

Publication number Publication date
US6448245B1 (en) 2002-09-10
US20020115665A1 (en) 2002-08-22
WO2001082919A2 (en) 2001-11-08
WO2001082919A3 (en) 2002-05-10
WO2001082919B1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
AU2001280599A1 (en) Compounds and methods
AU2001251358A1 (en) Prion-binding ligands and methods of using same
AU2001253418A1 (en) Compounds and methods
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
AU2001234088A1 (en) TNF-alpha inhibitors
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002225894A1 (en) Methods and compositions for the control of coccidiosis
AU2001259817A1 (en) Methods of and compounds for inhibiting calpains
AU1488501A (en) Methods of inhibiting metastasis
AU2001286983A1 (en) Method of treatment
AU2001243394A1 (en) Compounds and methods
AU2001241468A1 (en) Method of and system for counterfeit prevention
AU2002220036A1 (en) Method and system for improving stability of photomasks
AU2001294258A1 (en) Method of purifying plavastatin
AUPQ872300A0 (en) Compounds and methods
AU2001261676A1 (en) Method and reagent for the inhibition of erg
AU5261701A (en) Method for purification of tetrafluoromethane and use thereof
AU2002214189A1 (en) Methods of identifying inhibitory compounds and uses thereof
AU2001232245A1 (en) Tnf- alpha inhibitors
AU2001252884A1 (en) Method of dopamine inhibition using l-threo-methylphenidate
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU2001278951A1 (en) Compounds and methods
AUPQ904100A0 (en) Method of encryption
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
AU2002235277A1 (en) Compounds and methods